Alzheimer's disease

News

SEC charges Cassava over 'misleading' Alzheimer's claims

The US financial regulator has accepted a $40 million-plus settlement from Cassava Sciences and two of its former executives for making what it alleges are misleading statements about the r

News

traditional red and black painted bamboo walkway in Japan

Lilly gets second approval, in Japan, for Alzheimer's drug

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug.

News

Lilly ramps up Irish manufacturing investment by $1bn

Eli Lilly has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.

Digital

Mixed reactions among HCPs as lecanemab and donanemab secure...

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease.

News

UK first country in Europe to clear Leqembi, but NICE says n...

The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outw

News

Lilly's tau drug for Alzheimer's flunks phase 2 test

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug targ

SEC charges Cassava over 'misleading' Alzheimer's claims

Lilly gets second approval, in Japan, for Alzheimer's drug

Lilly ramps up Irish manufacturing investment by $1bn

Mixed reactions among HCPs as lecanemab and donanemab secure...

UK first country in Europe to clear Leqembi, but NICE says n...

Lilly's tau drug for Alzheimer's flunks phase 2 test

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Alzheimer's disease

Editor's Picks